Member
Paracrine
Paracrine develops regenerative therapies for chronic wound care, leveraging autologous cell-based treatments and real-time AI platforms to enhance healing precision, predictability, and efficiency. The company operates globally, focusing on scalable and cost-effective biological solutions that integrate advanced machine learning for improved patient outcomes.
Industries
biotechnology
Nr. of Employees
small (1-50)
Patents
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
2023-04-25 • US-11633382-B2
View DetailsMethod of deriving mesenchymal stem cells from ES cells using FGF2
2015-02-24 • US-8962318-B2
View Details
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
2023-04-25 • US-11633382-B2
View DetailsMethod of deriving mesenchymal stem cells from ES cells using FGF2
2015-02-24 • US-8962318-B2
View DetailsProducts
Stromal Vascular Therapy
Autologous cell-based therapy for chronic wound healing, using regenerative cells from the patient's own adipose tissue.
AI Platform for Wound Care
Suite of AI-powered software modules supporting clinical decision-making, patient monitoring, and outcome prediction for regenerative wound therapies.
Stromal Vascular Therapy
Autologous cell-based therapy for chronic wound healing, using regenerative cells from the patient's own adipose tissue.
AI Platform for Wound Care
Suite of AI-powered software modules supporting clinical decision-making, patient monitoring, and outcome prediction for regenerative wound therapies.
Expertise Areas
- Regenerative wound care
- Autologous cell therapy
- Artificial intelligence in medicine
- Remote patient monitoring
Key Technologies
- Machine learning
- Cell-based regenerative therapy
- Mobile health monitoring platforms
- Predictive analytics